Brokerages Anticipate Eli Lilly and Company (NYSE:LLY) Will Post Quarterly Sales of $6.91 Billion

Analysts predict that Eli Lilly and Company (NYSE:LLYGet Rating) will announce $6.91 billion in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Eli Lilly and’s earnings. The lowest sales estimate is $6.70 billion and the highest is $7.13 billion. Eli Lilly and reported sales of $6.74 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.5%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Eli Lilly and will report full year sales of $29.01 billion for the current year, with estimates ranging from $28.90 billion to $29.17 billion. For the next year, analysts forecast that the company will post sales of $30.68 billion, with estimates ranging from $30.23 billion to $31.41 billion. Zacks’ sales calculations are an average based on a survey of research analysts that follow Eli Lilly and.

Eli Lilly and (NYSE:LLYGet Rating) last issued its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.30. The firm had revenue of $7.81 billion during the quarter, compared to analysts’ expectations of $7.29 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. Eli Lilly and’s revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.87 earnings per share.

A number of research firms have issued reports on LLY. Wells Fargo & Company boosted their price target on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Mizuho boosted their price target on Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Bank of America boosted their price target on Eli Lilly and from $300.00 to $315.00 in a research report on Thursday, March 17th. The Goldman Sachs Group boosted their price target on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Finally, StockNews.com downgraded Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $302.56.

Shares of NYSE:LLY traded up $0.81 during midday trading on Monday, reaching $291.63. The company’s stock had a trading volume of 2,337,673 shares, compared to its average volume of 2,662,391. The firm has a market cap of $277.10 billion, a price-to-earnings ratio of 43.20, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60. Eli Lilly and has a 1 year low of $193.11 and a 1 year high of $314.00. The business has a 50 day moving average price of $289.22 and a 200 day moving average price of $266.49.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Monday, May 16th will be given a $0.98 dividend. The ex-dividend date of this dividend is Friday, May 13th. This represents a $3.92 dividend on an annualized basis and a yield of 1.34%. Eli Lilly and’s dividend payout ratio (DPR) is 58.07%.

In other news, major shareholder Lilly Endowment Inc sold 139,045 shares of the stock in a transaction on Friday, April 8th. The stock was sold at an average price of $310.79, for a total transaction of $43,213,795.55. Following the completion of the sale, the insider now owns 105,573,810 shares in the company, valued at approximately $32,811,284,409.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Ilya Yuffa sold 1,000 shares of the stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $237.45, for a total value of $237,450.00. The disclosure for this sale can be found here. Insiders sold 1,088,551 shares of company stock valued at $307,943,730 over the last 90 days. 0.12% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. McLean Asset Management Corp increased its holdings in shares of Eli Lilly and by 2.4% during the first quarter. McLean Asset Management Corp now owns 1,405 shares of the company’s stock worth $402,000 after buying an additional 33 shares in the last quarter. Affiance Financial LLC increased its holdings in shares of Eli Lilly and by 1.9% during the first quarter. Affiance Financial LLC now owns 1,835 shares of the company’s stock worth $525,000 after buying an additional 35 shares in the last quarter. Ashfield Capital Partners LLC increased its holdings in shares of Eli Lilly and by 0.5% in the first quarter. Ashfield Capital Partners LLC now owns 7,975 shares of the company’s stock valued at $2,284,000 after purchasing an additional 36 shares in the last quarter. American Money Management LLC increased its holdings in shares of Eli Lilly and by 0.8% in the first quarter. American Money Management LLC now owns 4,759 shares of the company’s stock valued at $1,363,000 after purchasing an additional 36 shares in the last quarter. Finally, Koshinski Asset Management Inc. increased its holdings in shares of Eli Lilly and by 0.8% in the first quarter. Koshinski Asset Management Inc. now owns 4,849 shares of the company’s stock valued at $1,389,000 after purchasing an additional 38 shares in the last quarter. Institutional investors own 82.75% of the company’s stock.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.